Mark J. Ratain to Drug Interactions
This is a "connection" page, showing publications Mark J. Ratain has written about Drug Interactions.
Connection Strength
1.845
-
Unmet needs in preventing adverse drug-drug interactions. Clin Adv Hematol Oncol. 2013 Aug; 11(8):520-1.
Score: 0.446
-
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware. J Clin Pharmacol. 2022 08; 62(8):925-927.
Score: 0.205
-
Drug-Drug Interactions With Oral Antineoplastic Agents. JAMA Oncol. 2017 06 01; 3(6):736-738.
Score: 0.146
-
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. Clin Cancer Res. 2013 Nov 01; 19(21):6039-43.
Score: 0.113
-
Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4.
Score: 0.112
-
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
Score: 0.095
-
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer. 2009 Jul; 45(11):1904-8.
Score: 0.083
-
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007 Oct; 82(4):381-8.
Score: 0.074
-
The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8.
Score: 0.073
-
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9.
Score: 0.071
-
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46.
Score: 0.068
-
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol. 2003 Jul 15; 21(14):2633-5.
Score: 0.056
-
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
Score: 0.051
-
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.
Score: 0.042
-
Drug combinations: dangerous liaisons or great expectations? Ann Oncol. 1999 Apr; 10(4):375-6.
Score: 0.041
-
Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther. 1993 Oct; 54(4):421-9.
Score: 0.028
-
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.
Score: 0.024
-
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol. 2011 Jun; 71(6):917-20.
Score: 0.024
-
Dose-escalation models for combination phase I trials in oncology. Eur J Cancer. 2010 Nov; 46(16):2870-8.
Score: 0.023
-
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Jan; 38(1):32-9.
Score: 0.022
-
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
Score: 0.016
-
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
Score: 0.015
-
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
Score: 0.010
-
Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun; 19(3 Suppl 9):84-9.
Score: 0.006